news
Second COVID-19 vaccine ‘Spikevax’ is approved by the FDA
The FDA has approved a second vaccine, marketed as Spikevax, shown to be 93 percent effective in preventing COVID-19.
List view / Grid view
Vaccines
news
MCAP for top bio/pharma companies reached $3.4 trillion in 2021
Market capitalisation (MCAP) for the top bio/pharma companies grew 24.9 percent in 2021, with BioNTech and Moderna entering the top 20 for the first time.
whitepaper
Playbook: Critical cold chain shipments best practices
Learn how the pharma supply chain is evolving, the role of real-time data in critical cold chain shipments and how to increase & improve visibility.
news
First patients dosed in HIV vaccine immunogens trial
Moderna and IAVI take steps towards HIV vaccination, with initiation of a trial dosing patients with HIV immunogens delivered by mRNA.
news
New studies look to assess immunogenicity of Omicron-based vaccines
A new clinical study by Pfizer Inc. and BioNTech SE, and Phase II study by Moderna, are seeking to evaluate the immunogenicity and safety of Omicron-based vaccines and boosters.
news
Scientists behind mRNA vaccine technologies win Frontiers of Knowledge Award
Katalin Karikó, Robert Langer and Drew Weissman win BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine for driving the advance of messenger RNA (mRNA) therapeutics.
whitepaper
Guide: How real-time tracking supports pharma distribution
This guide explores critical concepts that supply chain professionals need to know about tracking and analysing cold chain pharmaceutical shipments.
news
International regulators call for multivalent COVID-19 vaccines
Regulators encourage the development of bivalent or multivalent variant COVID-19 vaccines to continue to combat the disease and its variants.
news
Could COVID-19 vaccines be freeze dried?
US researchers have been granted $930,000 to develop a freeze drying technique for mRNA-based COVID-19 vaccines.
article
Key challenges for bio/pharmaceutical manufacturing 2022
What are the top six challenges facing pharmaceutical and biopharmaceutical manufacturers in 2022? We spoke to representatives from four contract manufacturing and development organisations (CDMOs) – Samsung Biologics, Lonza, MedPharm and Genezen – to find out.
![The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/GSK-3-300x278.jpg)
![The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/GSK-3-e1624534468322.jpg)
news
Tony Wood to replace Dr Hal Barron as GSK’s CSO
Tony Wood will assume accountability for R&D across GSK’s portfolio and pipeline from Dr Hal Barron on 1 August 2022.
news
mRNA COVID-19 vaccines safe for pregnant women, finds EMA review
A review of studies involving 65,000 pregnancies suggests mRNA COVID-19 vaccines do not increase the risk of pregnancy complications.
news
Promising results for COVID-19 and pneumococcal vaccine co-administration
Pfizer reveals co-administering its Prevnar 20™ pneumococcal vaccine and a booster dose of Comirnaty® COVID-19 vaccine was safe and immunogenic.
webinar
The path forward — Altasciences’ approach to project management
11 January 2022 | By Altasciences
Discover the opportunities Altasciences' hybrid approach to project management can offer your drug development programme.
news
Pfizer and BioNTech to develop mRNA shingles vaccine
New collaboration between Pfizer and BioNTech will develop an mRNA vaccine to combat shingles (herpes zoster virus).
